Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol

Katharine Patrick; Rachel Wade; Nicholas Goulden; Clare Rowntree; Rachael Hough; Anthony V. Moorman; Christopher D. Mitchell; Ajay Vora

doi:10.1111/bjh.12739

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol

Katharine Patrick, Rachel Wade, Nicholas Goulden, Clare Rowntree, Rachael Hough, Anthony V. Moorman, Christopher D. Mitchell, Ajay Vora

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

We report the outcome for children and young people with Down syndrome-associated acute lymphoblastic leukaemia (DS-ALL) treated on a contemporary protocol. Compared with non-DS ALL, patients with DS-ALL had an inferior event-free survival (65·6% vs. 87·7% at 5 years; P < 0·00005) and overall survival (70·0% vs. 92·2%; P < 0·00005). Excess treatment-related mortality - was primarily responsible for the worse outcomes for DS-ALL (21·6% at 5 years, vs. 3·3%, P < 0·00005). Minimal residual disease (MRD) risk status was highly discriminant for relapse in DS patients with 0/28 relapses in the MRD low risk group.

Original language	English (US)
Pages (from-to)	552-555
Number of pages	4
Journal	British journal of haematology
Volume	165
Issue number	4
DOIs	https://doi.org/10.1111/bjh.12739
State	Published - May 2014
Externally published	Yes

Keywords

Down syndrome
Lymphoblastic leukaemia
Treatment

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.12739

Cite this

@article{854ccabd46bf4747bd5ed6e54af4b86d,

title = "Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol",

abstract = "We report the outcome for children and young people with Down syndrome-associated acute lymphoblastic leukaemia (DS-ALL) treated on a contemporary protocol. Compared with non-DS ALL, patients with DS-ALL had an inferior event-free survival (65·6% vs. 87·7% at 5 years; P < 0·00005) and overall survival (70·0% vs. 92·2%; P < 0·00005). Excess treatment-related mortality - was primarily responsible for the worse outcomes for DS-ALL (21·6% at 5 years, vs. 3·3%, P < 0·00005). Minimal residual disease (MRD) risk status was highly discriminant for relapse in DS patients with 0/28 relapses in the MRD low risk group.",

keywords = "Down syndrome, Lymphoblastic leukaemia, Treatment",

author = "Katharine Patrick and Rachel Wade and Nicholas Goulden and Clare Rowntree and Rachael Hough and Moorman, {Anthony V.} and Mitchell, {Christopher D.} and Ajay Vora",

year = "2014",

month = may,

doi = "10.1111/bjh.12739",

language = "English (US)",

volume = "165",

pages = "552--555",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol

AU - Patrick, Katharine

AU - Wade, Rachel

AU - Goulden, Nicholas

AU - Rowntree, Clare

AU - Hough, Rachael

AU - Moorman, Anthony V.

AU - Mitchell, Christopher D.

AU - Vora, Ajay

PY - 2014/5

Y1 - 2014/5

N2 - We report the outcome for children and young people with Down syndrome-associated acute lymphoblastic leukaemia (DS-ALL) treated on a contemporary protocol. Compared with non-DS ALL, patients with DS-ALL had an inferior event-free survival (65·6% vs. 87·7% at 5 years; P < 0·00005) and overall survival (70·0% vs. 92·2%; P < 0·00005). Excess treatment-related mortality - was primarily responsible for the worse outcomes for DS-ALL (21·6% at 5 years, vs. 3·3%, P < 0·00005). Minimal residual disease (MRD) risk status was highly discriminant for relapse in DS patients with 0/28 relapses in the MRD low risk group.

AB - We report the outcome for children and young people with Down syndrome-associated acute lymphoblastic leukaemia (DS-ALL) treated on a contemporary protocol. Compared with non-DS ALL, patients with DS-ALL had an inferior event-free survival (65·6% vs. 87·7% at 5 years; P < 0·00005) and overall survival (70·0% vs. 92·2%; P < 0·00005). Excess treatment-related mortality - was primarily responsible for the worse outcomes for DS-ALL (21·6% at 5 years, vs. 3·3%, P < 0·00005). Minimal residual disease (MRD) risk status was highly discriminant for relapse in DS patients with 0/28 relapses in the MRD low risk group.

KW - Down syndrome

KW - Lymphoblastic leukaemia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84899488064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899488064&partnerID=8YFLogxK

U2 - 10.1111/bjh.12739

DO - 10.1111/bjh.12739

M3 - Article

C2 - 24428704

AN - SCOPUS:84899488064

SN - 0007-1048

VL - 165

SP - 552

EP - 555

JO - British journal of haematology

JF - British journal of haematology

IS - 4

ER -

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this